MX9707479A - Composicion y proceso para la prevencion y tratamiento de las reacciones de hipersensibilidad cutanea de manifestacion retardada. - Google Patents

Composicion y proceso para la prevencion y tratamiento de las reacciones de hipersensibilidad cutanea de manifestacion retardada.

Info

Publication number
MX9707479A
MX9707479A MX9707479A MX9707479A MX9707479A MX 9707479 A MX9707479 A MX 9707479A MX 9707479 A MX9707479 A MX 9707479A MX 9707479 A MX9707479 A MX 9707479A MX 9707479 A MX9707479 A MX 9707479A
Authority
MX
Mexico
Prior art keywords
treatment
prevention
composition
hypersensitivity reactions
cutaneous
Prior art date
Application number
MX9707479A
Other languages
English (en)
Other versions
MXPA97007479A (es
Inventor
Emmett Clemente
Robert W Mendes
Aloysius O Anaebonam
Mumtaz Ahmed
Original Assignee
Ascent Pediatrics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascent Pediatrics Inc filed Critical Ascent Pediatrics Inc
Publication of MX9707479A publication Critical patent/MX9707479A/es
Publication of MXPA97007479A publication Critical patent/MXPA97007479A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a un proceso y composicion farmacéutica para la prevencion y tratamiento de las reacciones de hipersensibilidad cutánea (Tipo IV A) de manifestacion retardada, en humanos. La composicion farmacéutica consta de un compuesto de cromona de la formula (I) o éste, disuelto o disperso en un portador farmacologicamente aceptable. De acuerdo con el proceso, una cantidad preventiva o terapéuticamente efectiva de la composicion se administra por vía topica en el sitio de un paciente humano que requiera este tratamiento, es decir el área susceptible a exposicion al antígeno o el sitio de una reaccion cutánea del tipo IV A.
MXPA/A/1997/007479A 1995-04-03 1997-09-30 Composicion y proceso para la prevencion y tratamiento de las reacciones de hipersensibilidad cutanea de manifestacion retardada MXPA97007479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41572195A 1995-04-03 1995-04-03
US415721 1995-04-03

Publications (2)

Publication Number Publication Date
MX9707479A true MX9707479A (es) 1998-06-28
MXPA97007479A MXPA97007479A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
EP0818998A4 (en) 2000-07-12
AU5321996A (en) 1996-10-23
EP0818998A1 (en) 1998-01-21
WO1996031203A1 (en) 1996-10-10
ZA962637B (en) 1996-07-26
CA2216363A1 (en) 1996-10-10
AU715131B2 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
GEP20043216B (en) Orally Administered Controlled Drug Delivery System
MX9700081A (es) Composiciones farmaceuticas de tacrina.
NZ508526A (en) Opioid formulations for treating pain
AU6286294A (en) Guanidine derivatives useful in therapy
RU95107881A (ru) Фармацевтическая композиция для лечения аллергических заболеваний, способ антигистаминного лечения, применение композиции для получения лекарственного препарата
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
TR199801115T2 (xx) Kinazolin t�revleri.
HK1035336A1 (en) Use of preparations for the application of antiseptic agents and/or agents promoting the healing of wounds to the lower respiratory tract
MX9707197A (es) Compuestos triciclicos de urea que son utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proliferativas.
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
BR9608435A (pt) Metodo para medicação do sistema de controle inflatório e de reações inflamatórias adversas e para produção de composto para o tratamento da patologia de reações inflamatórias adversas.
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
ZA962635B (en) Composition and process for prevention and treatment of cutaneous immediate hypersensitivity reactions
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
MX9707479A (es) Composicion y proceso para la prevencion y tratamiento de las reacciones de hipersensibilidad cutanea de manifestacion retardada.
MD1504F2 (ro) Aplicare a dimeticonei în calitate de ingredient activ în compoziţie farmaceutică pentru tratamentul aftelor şi stomatitelor şi compoziţie farmaceutică conţinând dimeticonă
GEP20043231B (en) Resorcinol Composition
WO1996030016A3 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
PL371264A1 (en) Method for the treatment of bone disorders
WO2001007029A3 (en) Substituted guanidines and the use thereof
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis